DMD Deal With Summit Is 'Low Risk, High Reward' For Sarepta

0 Comments 8 view(s)
<b>Sarepta Therapeutics Inc</b> (NASDAQ: <a href="">SRPT</a>) forged a deal with <b>Summit Therapeutics PLC (ADR)</b> (NASDAQ: <a href="">SMMT</a>) to develop its utrophin pipeline in exchange for European rights and a Latin America option.

Latest Ratings for SMMT

Date Firm Action From To
Sep 2016 H.C. Wainwright Initiates Coverage on Buy
Jun 2016 Janney Capital Initiates Coverage on Buy
Feb 2016 Canaccord Genuity Initiates Coverage on Buy

View More Analyst Ratings for SMMT

View the Latest Analyst Ratings